Division of Sellas Life Sciences Group Inc.
Latest From Apthera Inc.
Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.
The University of Texas MD Anderson Cancer Center is continuing its legacy of licensing oncology discoveries to pharmaceutical companies via a collaboration with GlaxoSmithKline through which the cancer center may earn more than $335 million in upfront and milestone payments plus royalties on sales of therapeutic antibodies that activate OX40 receptors on the surface of T cells to mount an immune system attack.
Galena Biopharma, a US oncology-focused company, said that it has closed on its underwritten public offering for gross proceeds of about $14.5 million. consisted of 9.75 million shares of its common stock at $1.50 per share,.
Galena Biopharma, a US firm focused on oncology, will net $11.6 million to advance its cancer immunotherapy NeuVax from the sale of 8.5 million shares of common stock at $1.50 per share in an offering set to close on 11 April.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Sellas Life Sciences Group Inc.
- Senior Management
Mark W Schwartz, PhD, Pres. & CEO
Robert E Kennedy, CFO
- Contact Info
Phone: (480) 348-9707
8418 E. Shea Blvd.
Scottsdale, AZ 85260
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.